NGL Fine-Chem Limited (NGLFINE) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.5B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +21.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,203 – ₹3,206 · fair‑value band ₹993.22 – ₹2,108 · the ₹3,206 price screens above the ₹1,324 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
NGL Fine-Chem Limited (NGLFINE) currently trades at ₹3,206, while our model-based Fair Value estimate is ₹1,324 — implying the stock looks roughly 58.7% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, NGL Fine-Chem Limited generated revenue of ₹5.0B at a net margin of 9.6%. Revenue grew 57.2% year over year. It earns a return on equity of 15.7%. Net debt stands at ₹1.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
NGL Fine-Chem Limited reported revenue of ₹5.0B in FY2026 versus ₹3.2B in FY2022, a compound +12.1%/yr. Reported net income was ₹481M in FY2026, compounding −0.9%/yr from FY2022.
Is NGLFINE fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NGL Fine-Chem Limited (NGLFINE) undervalued?
What is the fair value of NGLFINE?
What is the quality score of NGLFINE?
What is the revenue of NGL Fine-Chem Limited (NGLFINE)?
What is the net profit margin of NGLFINE?
Does NGL Fine-Chem Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.